Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey.

Alexis D Ritvo, D E Foster, Christy Huff, A J Reid Finlayson, Bernard Silvernail, Peter R Martin
Author Information
  1. Alexis D Ritvo: Department of Psychiatry, University of Colorado School of Medicine, Aurora, Colorado, United States of America. ORCID
  2. D E Foster: Benzodiazepine Action Work Group, Colorado Consortium for Prescription Drug Abuse Prevention, Aurora, Colorado, United States of America. ORCID
  3. Christy Huff: Benzodiazepine Information Coalition, Midvale, Utah, United States of America. ORCID
  4. A J Reid Finlayson: Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America. ORCID
  5. Bernard Silvernail: Alliance for Benzodiazepine Best Practices, Portland, Oregon, United States of America. ORCID
  6. Peter R Martin: Department of Psychiatry and Behavioral Sciences and Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.

Abstract

BACKGROUND: Acute benzodiazepine withdrawal has been described, but literature regarding the benzodiazepine-induced neurological injury that may result in enduring symptoms and life consequences is scant.
OBJECTIVE: We conducted an internet survey of current and former benzodiazepine users and asked about their symptoms and adverse life events attributed to benzodiazepine use.
METHODS: This is a secondary analysis of the largest survey ever conducted with 1,207 benzodiazepine users from benzodiazepine support groups and health/wellness sites who completed the survey. Respondents included those still taking benzodiazepines (n = 136), tapering (n = 294), or fully discontinued (n = 763).
RESULTS: The survey asked about 23 specific symptoms and more than half of the respondents who experienced low energy, distractedness, memory loss, nervousness, anxiety, and other symptoms stated that these symptoms lasted a year or longer. These symptoms were often reported as de novo and distinct from the symptoms for which the benzodiazepines were originally prescribed. A subset of respondents stated that symptoms persisted even after benzodiazepines had been discontinued for a year or more. Adverse life consequences were reported by many respondents as well.
LIMITATIONS: This was a self-selected internet survey with no control group. No independent psychiatric diagnoses could be made in participants.
CONCLUSIONS: Many prolonged symptoms subsequent to benzodiazepine use and discontinuation (benzodiazepine-induced neurological dysfunction) have been shown in a large survey of benzodiazepine users. Benzodiazepine-induced neurological dysfunction (BIND) has been proposed as a term to describe symptoms and associated adverse life consequences that may emerge during benzodiazepine use, tapering, and continue after benzodiazepine discontinuation. Not all people who take benzodiazepines will develop BIND and risk factors for BIND remain to be elucidated. Further pathogenic and clinical study of BIND is needed.

References

  1. Psychother Psychosom. 2021;90(3):207-208 [PMID: 33556941]
  2. CNS Drugs. 2004;18(1):37-48 [PMID: 14731058]
  3. Forensic Sci Int. 2012 Jul 10;220(1-3):111-7 [PMID: 22391477]
  4. Qual Health Res. 2017 Nov;27(13):2030-2041 [PMID: 28891380]
  5. Addiction. 2021 Jun;116(6):1301-1303 [PMID: 33449443]
  6. Aust Prescr. 2015 Oct;38(5):152-5 [PMID: 26648651]
  7. Curr Neuropharmacol. 2020;18(9):809-837 [PMID: 31933443]
  8. Handb Exp Pharmacol. 2018;252:383-410 [PMID: 30367253]
  9. Int Pharmacopsychiatry. 1981;16(4):235-44 [PMID: 6121767]
  10. Addiction. 2011 Dec;106(12):2086-109 [PMID: 21714826]
  11. Ann Pharm Fr. 2009 Nov;67(6):408-13 [PMID: 19900604]
  12. Psychother Psychosom. 2020;89(5):283-306 [PMID: 32259826]
  13. Br J Addict. 1987 Jun;82(6):665-71 [PMID: 2886145]
  14. Psychother Psychosom. 2022;91(5):307-334 [PMID: 35504267]
  15. Ther Adv Psychopharmacol. 2023 Feb 6;13:20451253221145561 [PMID: 36760692]
  16. Eur Addict Res. 2022;28(5):377-381 [PMID: 36041417]
  17. Curr Opin Psychiatry. 2005 May;18(3):249-55 [PMID: 16639148]
  18. Ther Adv Psychopharmacol. 2022 Apr 25;12:20451253221082386 [PMID: 35499041]
  19. Br J Psychiatry. 1990 Aug;157:232-8 [PMID: 2224374]
  20. Br J Clin Pharmacol. 2014 Feb;77(2):239-41 [PMID: 23617374]
  21. Br J Clin Pharmacol. 2014 Feb;77(2):285-94 [PMID: 23126253]
  22. J Subst Abuse Treat. 1991;8(1-2):19-28 [PMID: 1675688]
  23. J Psychoactive Drugs. 1983 Jan-Jun;15(1-2):85-95 [PMID: 6136575]
  24. Psychiatry Res. 2012 Aug 15;198(3):457-62 [PMID: 22424905]
  25. Arch Clin Neuropsychol. 2018 Nov 01;33(7):901-911 [PMID: 29244060]
  26. Psychiatr Serv. 2019 Feb 1;70(2):97-106 [PMID: 30554562]
  27. Cochrane Database Syst Rev. 2018 Mar 15;3:CD011481 [PMID: 29543325]

MeSH Term

Humans
Amnesia
Anxiety
Anxiety Disorders
Control Groups
Benzodiazepines

Chemicals

Benzodiazepines

Word Cloud

Created with Highcharts 10.0.0symptomsbenzodiazepinesurveyneurologicallifeconsequencesbenzodiazepinesBINDbenzodiazepine-inducedusersusen=respondentsmayconductedinternetaskedadversetaperingdiscontinuedstatedyearreporteddiscontinuationdysfunctionBACKGROUND:AcutewithdrawaldescribedliteratureregardinginjuryresultenduringscantOBJECTIVE:currentformereventsattributedMETHODS:secondaryanalysislargestever1207supportgroupshealth/wellnesssitescompletedRespondentsincludedstilltaking136294fully763RESULTS:23specifichalfexperiencedlowenergydistractednessmemorylossnervousnessanxietylastedlongeroftendenovodistinctoriginallyprescribedsubsetpersistedevenAdversemanywellLIMITATIONS:self-selectedcontrolgroupindependentpsychiatricdiagnosesmadeparticipantsCONCLUSIONS:ManyprolongedsubsequentshownlargeBenzodiazepine-inducedproposedtermdescribeassociatedemergecontinuepeopletakewilldevelopriskfactorsremainelucidatedpathogenicclinicalstudyneededLong-termdysfunction:

Similar Articles

Cited By